Markets / Mutual funds / Index Funds (equity)
DSP Mutual Fund · Index & ETFs fund · Regular plan · IDCW
The investment objective of the Scheme is to generate returns that are commensurate with the performance of the Nifty Healthcare Index, subject to tracking error. There is no assurance that the investment objective of the Scheme will be achieved.
Bars: this plan; the thin mark is the Index Funds (equity) average (regular plans, growth option). Over a year: yearly averages (CAGR). Past returns do not guarantee future returns. Information only, not investment advice.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +2.2 | +3.1 | -3.4 | -1.4 | +3.7 | +2.2 | -2.7 | |||||
| 2026 | -5.1 | +7.1 | -4.5 | +4.9 | +3.1 | +4.8 | +4.0 | +1.1 | -4.8 | +1.9 | +2.2 |
Each month's change in NAV (the current month to the latest NAV).
Worked out from this plan's actual NAVs. SIP: invested on the first NAV of each month. Taxes and exit loads are not included. Past returns do not guarantee future returns. Information only, not investment advice.
| Share of fund | 30 Sept 2026 | 31 Aug 2026 | Change |
|---|---|---|---|
| Stocks held | 100.0% | 100.0% | +0.06 |
| Short positions | -0.4% | -0.1% | -0.29 |
| Cash & others | -0.0% | 0.0% | -0.06 |
| Top 10 stocks | 75.9% | 77.3% | -1.44 |
| Number of stocks | 20 | 20 | 0 |
Change is in percentage points. Bought more and cut back list stocks whose share of the fund moved by at least 0.25 points. A share can also move because the price changed, not only because the fund traded.
| Holding | % of fund |
|---|---|
| Sun Pharmaceutical Industries Limited INE044A01036 | 17.01% |
| Divi's Laboratories Limited INE361B01024 | 10.44% |
| Apollo Hospitals Enterprise Limited INE437A01024 | 7.43% |
| Laurus Labs Limited INE947Q01028 | 6.82% |
| Cipla Limited INE059A01026 | 6.70% |
| Dr. Reddy's Laboratories Limited INE089A01031 | 6.65% |
| Torrent Pharmaceuticals Limited INE685A01028 | 6.25% |
| Max Healthcare Institute Limited INE027H01010 | 6.12% |
| Lupin Limited INE326A01037 | 4.36% |
| Aurobindo Pharma Limited INE406A01037 | 4.09% |
| Fortis Healthcare Limited INE061F01013 | 3.55% |
| Glenmark Pharmaceuticals Limited INE935A01035 | 3.11% |
| Alkem Laboratories Limited INE540L01014 | 2.75% |
| Zydus Lifesciences Limited INE010B01027 | 2.55% |
| Mankind Pharma Limited INE634S01028 | 2.51% |
| IPCA Laboratories Limited INE571A01038 | 2.37% |
| Biocon Limited INE376G01013 | 2.28% |
| Gland Pharma Limited INE068V01023 | 2.04% |
| Krishna Institute Of Medical Sciences Limited INE967H01025 | 1.76% |
| Abbott India Limited INE358A01014 | 1.25% |
| Holding | % of fund |
|---|---|
| Net Receivables/Payables | -0.42% |
| Holding | % of fund |
|---|---|
| TREPS / Reverse Repo Investments | 0.38% |
From the fund house's monthly portfolio (dspim.com), as on 30 Sept 2026. Percentages are of the fund's net assets; short positions are negative. Published about ten days after each month ends.
Volatility: how much the NAV moves, as a yearly figure (higher = bumpier). Worst fall: the biggest drop from a high, in the NAV history we hold (from 20 Jun 2025).
The ranges the fund is allowed to hold, not what it holds today.
| Fund size (average AUM, July - September 2026) | ₹24.42 cr across all plans · this plan ₹0.48 cr |
| Fund house | DSP Mutual Fund |
| Category | Index & ETFs · Index Funds (equity) |
| Plan | Regular |
| Option | IDCW |
| Expense ratio (TER) | Direct 0.39% · Regular 1.07% (5 Nov 2026) |
| Minimum investment | ₹100 · additional ₹100 |
| Scheme code (AMFI) | 153595 |
| ISIN | INF740KA1WD5 |
| NAV date | 5 Nov 2026 |
Scheme details from the fund's scheme summary document filed with AMFI; expense ratios from AMFI's daily filings.
| Plan | NAV | 1 year |
|---|---|---|
| Direct · Growth | ₹11.9672 | +14.17% |
| Direct · IDCW | ₹11.9672 | +14.17% |
| Regular · Growth | ₹11.8560 | +13.42% |
| Fund | 1 year | 3 years (a year) |
|---|---|---|
| ICICI Prudential NASDAQ 100 Index Fund | +10.81% | +25.41% |
| Motilal Oswal S&P 500 Index Fund | +15.40% | +23.79% |
| ICICI Prudential Nifty Pharma Index Fund | +22.94% | +22.18% |
| Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund | +21.72% | +21.26% |
| ICICI Prudential Nifty Auto Index Fund | +4.46% | +20.29% |
| Motilal Oswal BSE Enhanced Value Index Fund | -2.47% | +19.95% |
| UTI Nifty 500 Value 50 Index Fund | +2.35% | +19.85% |
| Motilal Oswal BSE Enhanced Value Index Fund | -3.11% | +19.14% |
All Index Funds (equity) funds ranked › · Compare with others ›
Information only, not investment advice.
₹11.8560 as of 5 Nov 2026, from AMFI's official NAV data.
1 year: 13.42%
Both invest in the same portfolio. Direct plans are bought straight from the fund house and pay no distributor commission, so their expenses are lower and their NAV grows slightly faster.